Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma

American Journal of Hematology(2022)10.1002/ajh.26596Source: DataRank Database

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma is a research paper published in American Journal of Hematology (2022). On theSindex it has a DataRank of 0. It has been cited 30 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access30 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)OA: greenTopics (14)Linked Datasets (6)DataCite Reuse (6)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (21)

Ruta Brazauskas,Edward A. Stadtmauer ORCID,Marcelo C. Pasquini ORCID,Parameswaran Hari ORCID,Asad Bashey

Live enrichment

PubMed:35567778 PMC:PMC9659666

National Heart, Lung, and Blood Institute

Grant: K23 HL141445

National Institutes of Health

Grant: U10HL069294

NCI NIH HHS

Grant: P30 CA008748

NHLBI NIH HHS

Grant: UG1 HL069278

NHLBI NIH HHS

Grant: U24 HL138660

NCI NIH HHS

Grant: P30 CA014236

NHLBI NIH HHS

Grant: UG1 HL069286

NHLBI NIH HHS

Grant: UG1 HL069315

National Institutes of Health

Grant: 5U10HL069294-13

Blood & Marrow Transplant Clinical Trials Network Data Coordinating Center

National Institutes of Health

Grant: 5K23HL141445-02

Development and validation of a disease-relevant patient-reported outcome tool in light chain amyloidosis

greenLicense: Wiley Online Library User Agreement

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9659666

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26596

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/ajh.26596

https://doi.org/10.1002/ajh.26596

https://pubmed.ncbi.nlm.nih.gov/35567778

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansMultiple MyelomaHematopoietic Stem Cell TransplantationTransplantation, AutologousQuality of LifeMiddle Aged

Keywords

Quality of LifeHematopoietic Stem Cell TransplantationHumansMiddle AgedMultiple MyelomaTransplantation, Autologous

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

10.6084/m9.figshare.25150573.v1figshare

10.6084/m9.figshare.25150573figshare

Additional file 2 of Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

10.6084/m9.figshare.25150688.v1figshare

10.6084/m9.figshare.25150688figshare

Additional file 3 of Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

10.6084/m9.figshare.26676983.v1figshare

10.6084/m9.figshare.26676983figshare